The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Thyroid Cancer: A Lethal Endocrine Neoplasm
Abstract
This conference focuses on the controversies about managing thyroid cancer, emphasizing the possibility that the treatment of patients with potentially fatal thyroid cancer may be improved. Although the mortality rate from thyroid cancer is low, it is the highest among cancers affecting the endocrine glands (excluding the ovary). Exposure to radiation during childhood in the 1930s and 1940s increased the incidence of but not the mortality from thyroid cancer, because these tumors are mainly papillary cancers developing in young adults. These rates may change as the exposed cohort ages. Risk factors that increase mortality include older patient age and the growth characteristics of the tumor at diagnosis, the presence of distant metastases, and cell type (for example, the tall-cell variants of papillary cancer, follicular cancer [to be distinguished from the more benign follicular variant of papillary cancer], medullary cancer, and anaplastic cancer). Local metastases in lymph nodes do not seem to increase the risk for death from papillary cancer, but they do increase the risk for death from follicular and medullary cancer. In the latter, mortality is decreased by the early detection and treatment of patients with the familial multiple endocrine neoplasia syndrome 2a. There are excellent tumor markers for differentiated cancer of the parafollicular and of the follicular cells (serum calcitonin and serum thyroglobulin levels, respectively). Measuring the calcitonin level allows early diagnosis of familial medullary cancer, whereas measuring the thyroglobulin level, although useful only after total thyroidectomy, allows early recognition of recurrence or metastases of papillary or follicular cancer. Initial surgery, protocols for follow-up, and the use of radioiodine for the ablation of any residual thyroid and the treatment of metastatic cancer are discussed. Because these tumors resist currently available chemotherapy regimens, possible ways to increase the effectiveness of radioiodine therapy are considered as are new approaches to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
BRENNAN, M. D., BERGSTRALH, E. J., van HEERDEN, J. A., & McCONAHEY, W. M. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61170-7 · Cited by 764
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma
Tubiana, M., Schlumberger, M., Rougier, P., Laplanche, A., Benhamou, E., Gardet, P., Caillou, B., Travagli, J.-P., & Parmentier, C. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4<794::aid-cncr2820550418>3.0.co;2-z · Cited by 573
McCONAHEY, W. M., HAY, I. D., WOOLNER, L. B., van HEERDEN, J. A., & TAYLOR, W. F. (1986) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62641-x · Cited by 526
Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer
Maxon, H. R., Thomas, S. R., Hertzberg, V. S., Kereiakes, J. G., Chen, I.-W., Sperling, M. I., & Saenger, E. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310203091601 · Cited by 503
(1962) · PubMed · Cited by 467
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10
Mathew, C. G. P., Chin, K. S., Easton, D. F., Thorpe, K., Carter, C., Liou, G. I., Fong, S.-L., Bridges, C. D. B., Haak, H., Kruseman, A. C. N., et al. (1987) · Nature · doi:10.1038/328527a0 · Cited by 440
Fox, H. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.10.1016-d · Cited by 438
Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage
Simpson, N. E., Kidd, K. K., Goodfellow, P. J., McDermid, H., Myers, S., Kidd, J. R., Jackson, C. E., Duncan, A. M. V., Farrer, L. A., Brasch, K., et al. (1987) · Nature · doi:10.1038/328528a0 · Cited by 425
Cited by
Gilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
Ladenson, P. W., Braverman, L. E., Mazzaferri, E. L., Brucker-Davis, F., Cooper, D. S., Garber, J. R., Wondisford, F. E., Davies, T. F., DeGroot, L. J., Daniels, G. H., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371304 · Cited by 466
Self-citationNational Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
Self-citationPrognosis and Treatment of Brain Metastases in Thyroid Carcinoma
Chiu, A. C. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3637 · Cited by 295
Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy
DOW, K. H., FERRELL, B. R., & ANELLO, C. (1997) · Thyroid · doi:10.1089/thy.1997.7.613 · Cited by 289
Metadata
- Authors
- Robbins, J., Merino, M. J., Boice, J. D., Ron, E., Ain, K. B., Alexander, H. R., Norton, J. A., & Reynolds, J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1991-07-15
- Volume
- 115
- Issue
- 2
- Pages
- 133-147
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2091585840
- Cited by
- 253
- References
- 58
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid Cancer: A Lethal Endocrine Neoplasm. https://app.cochat.ai/papers/10.7326/0003-4819-115-2-133
- The paper
- Robbins, J., Merino, M. J., Boice, J. D., Ron, E., Ain, K. B., Alexander, H. R., Norton, J. A., & Reynolds, J. (1991). Thyroid Cancer: A Lethal Endocrine Neoplasm. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-115-2-133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.